{"groups":[{"description":"Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"FG000","title":"Vorinostat + Bortezomib"},{"description":"Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"FG001","title":"Placebo + Bortezomib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"112"},{"groupId":"FG001","numSubjects":"144"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"18"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"89"},{"groupId":"FG001","numSubjects":"61"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"62"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Not Treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"317"},{"groupId":"FG001","numSubjects":"320"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"315"},{"groupId":"FG001","numSubjects":"320"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"24"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"297"},{"groupId":"FG001","numSubjects":"296"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"637 participants were randomized to treatment and 635 participants received at least 1 dose of MK-0683 or placebo: 315 participants were treated with vorinostat + bortezomib and 320 participants were treated with placebo + bortezomib.","recruitmentDetails":"This study enrolled participants with an established diagnosis of multiple myeloma based on standard criteria that have received at least 1 but not more than 3 prior anti-myeloma regimens and have demonstrated progressive disease after the most recent treatment regimen. Additional inclusion and exclusion criteria applied."}